The Effect of Short-Term Glycemic Regulation with Gliclazide and Metformin on Postprandial Lipemia

Emral, Rıfat; Koseoglulari, Osman; Tonyukuk, Vedia; Uysal, Alper; Kamel, Nashwa; Çorapçıoğlu, Demet

doi:10.1055/s-2004-830536

Cited by 8 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most interesting perhaps was the PL inhibitory activity of the sulfonylurea drug GzD, the sulfonamide SfD and the basic drug OrP, which had not been previously reported to have such an activity. Short term use of GzD by diabetic patients was shown to improve postprandial lipemia (22), which might support our findings. More relevant, perhaps, were some recent reports which demonstrated the inhibition of the related enzyme diacylglycerol lipase by glycine sulfonamide derivatives that can be structurally related to GzD and SfD (23,24).…”

Section: Lipase Inhibitory Activitysupporting

confidence: 90%

Pancreatic lipase inhibitory activity of selected pharmaceutical agents

et al. 2018

View full text Add to dashboard Cite

Twenty-five structurally diverse compounds have been tested in vitro for their pancreatic lipase (PL) inhibitory activity. Despite the diversity of tested compounds, the relationship comprising structural attributes of the compounds could be established to correlate with the observed inhibitory activity. Compounds that exerted inhibitory action through surface activity were of different profile from the rest of compounds. When co-incubated with orlistat (OsT), important synergistic effects for some compounds (orphenadrine, gliclazide, cefuroxime and sulfacetamide) were revealed, while antagonistic effects were demonstrated for others (camphor sulfonic acid and dinitro salicylic acid). Docking studies for the most active molecules were performed and molecular interaction forces with the PL active site were identified. The results suggested co-binding of OsT along with the other inhibitor in the binding site in cases of synergistic effect but not in the case of antagonistic effect. These results were additionally supported by affinity capillary electrophoresis. In conclusion, synergistic lipase inhibitory activity between OsT and some other pharmaceutical compounds was demonstrated for the first time, which might help improve the pharmacological effect of OsT.

show abstract

Section: Lipase Inhibitory Activitysupporting

confidence: 90%

Pancreatic lipase inhibitory activity of selected pharmaceutical agents

et al. 2018

View full text Add to dashboard Cite

show abstract

“…20 The result of this study reveals that a regular administration of combination drug therapy for 90 days lowered lipid concentration. There was a slightly lower incidence of hypoglycemia (2%) as compared with previous studies.…”

Section: Discussionmentioning

confidence: 69%

Evaluation of Efficacy and Tolerability of Glimepiride and Metformin Combination

Pareek

Chandurkar²,

Zawar³

et al. 2013

American Journal of Therapeutics

View full text Add to dashboard Cite

The objectives of this study were to evaluate the efficacy and tolerability of glimepiride plus extended release metformin (MET) on glycemic control in patients with type-2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or MET. This was a prospective, open-labeled, multicentric study over 12 weeks. Patients who were diagnosed with type-2 diabetes and were uncontrolled on monotherapy with single oral hypoglycemic agents such as glimepiride or MET and characterized by glycosylated hemoglobin (HbA1c) ≥7% and ≤10% and fasting plasma glucose (FPG) ≥ 140 mg/dL were enrolled in this study. Treatment regimen was started at 1 mg of glimepiride plus 500 mg of MET once a day and was titrated to next dose level depending on the clinician's judgment, not exceeding a total daily dose of 8 mg of glimepiride and 2000 mg of MET. After 12-weektreatment, glimepiride plus MET combination showed improvement in metabolic control as assessed by changes in HbA1c, FPG, and post prandial glucose (PPG). Primary efficacy parameter, HbA1c, was significantly reduced to (7.65 ± 1.70) at the end of the treatment from the baseline value (8.35 ± 0.93) (P < 0.001). Of the patients, 65.79% showed ≥0.5% reduction in HbA1c and or HbA1c <7% at the end of the therapy. FPG and PPG were significantly reduced at the end of the therapy as compared with baseline values (P < 0.001). Moreover, the lipid profile was also improved during the treatment period. The addition of glimepiride to MET is an effective treatment for patients inadequately controlled on sulfonylurea or Met alone. A combination of glimepiride with MET achieves good glycemic control with better tolerability profile.

show abstract

“…In 2018, Pangeta et al reported positive and significant associations between glycemic control and the atherogenic indices of T2DM patients (36). Various doses of MET (1000-2550 mg/ day) generate significant changes in lipid profile indicators after a maximum of 3 months of treatment in a prospective controlled clinical trial setting (37,38). In the current investigation, which mirrors the real-world clinical practice situation, no significant variations in lipid profile indicators were seen following the arrangement for MET dosage titration and treatment duration.…”

Section: Discussionmentioning

confidence: 99%

The association of metformin dose up-titration and treatment duration with adiposity, lipid profile indicators, and serum leptin levels in T2DM Iraqi patients

Abdulrahman

Alatrakji

Al-Maliky³

et al. 2023

JHSCI

View full text Add to dashboard Cite

Introduction: Numerous factors, including age, gender, physical inactivity, insufficient dose, noncompliance, and drug-drug interactions, may contribute to significant intraindividual variation in metformin (MET) response. This study aims to determine the effect of Met dose and treatment duration on adiposity markers and serum leptin levels in Iraqi patients with type 2 diabetes. Methods: Between October 2021 and March 2022, a cross-sectional study at the Diabetes and Endocrinology Center in Baghdad included 150 type 2 diabetes mellitus (T2DM) patients with a disease duration of more than 1 year. Clinical and physical examinations were conducted before enrollment. We measured anthropometric variables such as body mass index, waist-to-hip ratio, and visceral adiposity index. We evaluated glycated hemoglobin, leptin, C-reactive protein, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), and triglycerides (TGs) in the serum. Results: Only the TC/HDL-c and TG/HDL-c ratios were significantly different after the data were arranged according to glycemic control level. Arrangement for MET doses and treatment duration, none of the evaluated parameters were significantly different (p > 0.05) between groups receiving different doses of MET for different durations, except visceral adiposity index (VAI), which shows a very slight decrease (p = 0.046) after more than 10 years of treatment. Pearson’s correlation analysis revealed a weak and significant association between waist circumference (WC) and hip circumference and MET doses, and a weak and significant association between WC, VAI, and TG levels and treatment duration. The other markers lacked a significant relationship with MET doses or duration of treatment. Conclusion: MET dose and duration of treatment were not significantly correlated with adiposity and lipid profiles in Iraqi patients with T2DM.

show abstract

The Effect of Short-Term Glycemic Regulation with Gliclazide and Metformin on Postprandial Lipemia

Cited by 8 publications

References 28 publications

Pancreatic lipase inhibitory activity of selected pharmaceutical agents

Pancreatic lipase inhibitory activity of selected pharmaceutical agents

Evaluation of Efficacy and Tolerability of Glimepiride and Metformin Combination

The association of metformin dose up-titration and treatment duration with adiposity, lipid profile indicators, and serum leptin levels in T2DM Iraqi patients

Contact Info

Product

Resources

About